General Info

Argos Therapeutics is funded by a broad syndicate of value-added life science investors, such as TVM, TFG Capital, MDS Capital, Intersouth Partners, Genechem, CDP Capital Technology Ventures, The Aurora Funds and ABN Amro Capital. The company was incorporated in 1997 and operated as Merix Bioscience prior to late 2004. The company s roots are embedded in Duke University, where the company founders developed a unique RNA-based vaccine technology. It specializes in technology related to the generation of dendritic cells and its current therapeutic development and is centered on its broad technology platform. Argos Therapeutics is positioned at the convergence of the scientific, clinical and investor communities and their expanding interest in autologous patient-specific vaccines. Argos Therapeutics is based in Durham, N.C.